lovastatin has been researched along with Apolipoprotein B-100, Familial Defective in 243 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (32.92) | 18.7374 |
| 1990's | 145 (59.67) | 18.2507 |
| 2000's | 15 (6.17) | 29.6817 |
| 2010's | 3 (1.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Giacomo, S; Mazza, F; Mesce, D; Morozzi, C; Pergolini, M; Stefanutti, C; Vitale, M | 1 |
| Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A | 1 |
| Blom, DJ; Chatelais, M; Gusarova, V; Lambert, G; Marais, AD; Passard, M; Petrides, F; Rye, KA; Sasiela, W; Schwahn, U; Thedrez, A | 1 |
| Illingworth, DR; Pappu, AS | 2 |
| Sinzinger, H | 2 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Bacon, SP; Illingworth, DR; Pappu, AS | 1 |
| Haba, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Sakai, Y; Takeda, R; Tatami, R; Wakasugi, T; Watanabe, A | 2 |
| Brown, MS; Goldstein, JL | 2 |
| Bilheimer, DW; Brown, MS; Goldstein, JL; Grundy, SM | 3 |
| Cho, M; Clauss, SB; Holmes, KW; Hopkins, P; Johnson-Levonas, AO; Kwiterovich, PO; Stein, E; Tate, A | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Cuthbert, JA; Lipsky, PE | 2 |
| De Boer, HH; Hendriks, T; Van Niekerk, JL | 1 |
| Bilheimer, DW; Grundy, SM | 1 |
| Matsuzawa, Y; Sudo, H; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Connor, WE; Illingworth, DR | 1 |
| Illingworth, DR | 4 |
| Illingworth, DR; Sexton, GJ | 1 |
| Bilheimer, DW | 2 |
| Hayashi, R; Hirobe, K; Kikkawa, T; Kishino, B; Matsuzawa, Y; Yamamoto, A | 1 |
| Koizumi, J; Mabuchi, H; Sakai, T; Sakai, Y; Takeda, R; Wakasugi, T; Watanabe, A; Yoshimura, A | 1 |
| Haba, T; Kametani, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Takeda, R; Takeshita, H; Tatami, R; Ueda, K; Ueda, R; Wakasugi, T; Watanabe, A; Yoshimura, A | 1 |
| Abrahamson, D; Detrano, RC; Franklin, SS; Henein, N; Kashyap, ML; Kukes, G; Rosenzweig, B; Teng, W; Willner, R; Wong, ND | 1 |
| Cummings, MH; Naoumova, R; Quiney, JR; Sönksen, PH; Thompson, GR; Umpleby, M; Watts, GF | 1 |
| Hansen, JB; Hanssen, TA; Huseby, KR; Huseby, NE; Nordøy, A; Sandset, PM | 1 |
| Olbricht, CJ | 1 |
| Homma, Y; Kobayashi, T; Nakamura, H; Ozawa, H; Sakane, H; Yamaguchi, H | 1 |
| Bates, MC; Robinson, PA; Wallace, MB; Warren, SG | 1 |
| Bell, HH; Chiarelli, T; Dittmeier, G; Vacek, JL; White, J | 1 |
| Dowell, FJ; Hamilton, CA; Lindop, GB; Reid, JL | 1 |
| de Bruin, TW; Koomans, HA; Rabelink, TJ; Stroes, ES | 1 |
| Richter, WO; Schwandt, P | 1 |
| Assadollahi, F; Beaumont, JL; Buxtorf, JC; Cavallero, E; Jacotot, B | 1 |
| Pedreño, J; Ros, E; Sánchez, JL; Zambón, D | 1 |
| Bär, PR; Erkelens, DW; Geerdink, RA; Smit, JW | 1 |
| Bargossi, AM; Battino, M; Di Giulio, R; Fiorella, PL; Gaddi, A; Grossi, G | 1 |
| Knops, RE; Kroon, AA; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Amouyel, P; Brousseau, T; Devulder, B; Fruchart, JC; Lecerf, JM; Luc, G | 1 |
| Ceska, R; Kvasilová, M; Procházková, R; Sobra, J | 2 |
| Kontula, K; Ojala, JP; Sarna, S; Tikkanen, MJ; Turtola, H; Vuorio, AF | 1 |
| Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Procházková, R; Sobra, J; Wilczek, H | 1 |
| Shepherd, J | 1 |
| Kolesár, P; Kupcová, V; Mojto, V; Raslová, K; Ulicná, O | 1 |
| Davies, G; Kitano, Y; Maher, VM; Matthews, S; Mir, A; Neuwirth, C; Prescott, RJ; Rees, A; Shortt, MB; Thompson, GR | 1 |
| Weatherall, D | 1 |
| Engelhardt, JF; Grossman, M; Kozarsky, K; Lupien, PJ; Muller, D; Raper, SE; Stein, EA; Wilson, JM | 1 |
| de Graaf, J; Demacker, PN; Stalenhoef, AF | 1 |
| Hohlfeld, T; Kaczmarek, D; Schrör, K; Wambach, G | 1 |
| Gurevich, VS; Konstantinov, VO; Lipovetskiĭ, BM; Mikhaĭlova, IA; Vasil'eva, LE | 1 |
| Ball, M; Chisholm, A; Sutherland, W | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Heikkilä, JI; Kervinen, K; Kesäniemi, YA; Savolainen, MJ | 1 |
| Kruse, W; Nikolaus, T; Rampmaier, J; Schlierf, G; Weber, E | 1 |
| Feher, MD; Knight, BL; Lant, AF; Mayne, PD; Patel, DD; Soutar, AK; Webb, JC | 1 |
| Bais, R; Clifton, PM; Coyle, P; Hosking, J; Kusenic, B; Nestel, PJ; Roach, PD; Thomas, DW; Wight, MB | 1 |
| Carmena, R; Davignon, J; Lussier-Cacan, S; Mailloux, H; Roederer, G | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| Endo, A; Pavlov, MY; Repin, VS; Sviridov, DD | 1 |
| de Villiers, W; Graadt van Roggen, F; Jeenah, M; Marais, D; Seftel, H; September, W | 1 |
| Gudnason, V; Humphries, SE; Lloyd, JK; Muller, DP | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Blaichman, S; Clarke, JT; Clarson, C; Gagné, C; Hayden, M; Lambert, J; Lambert, M; Langlois, S; Lévy, E; Lupien, PJ; Parsons, H; Potvin, D; Rose, V; Stephure, DK; Wolfe, BM | 1 |
| Balestrieri, GP; Di Stefano, O; Maffi, V; Salvi, A; Scalvini, T; Sleiman, I; Spandrio, S | 1 |
| Hjermann, I; Leren, TP | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Genest, J; Qiu, S; Yu, L | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Foo, JI; Mamotte, CD; Sturm, M; Taylor, RR; van Bockxmeer, FM | 1 |
| Hehnke, U; Kaffarnik, H; Schwartz, T; Steinmetz, A | 1 |
| Aznar, J; Carmena, R; Gil, L; Lluch, I; Martí, R; Martínez, M; Vayá, A | 2 |
| Gørbitz, C; Ose, L; Retterstøl, K; Stugaard, M | 1 |
| Lipovetskiĭ, BM | 1 |
| Lingenhel, A; Pilcher, G; Raal, FJ; Rubinsztein, DC; Utermann, G | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Avery, BR | 1 |
| Chan, P; Jones, C; Lafrenière, R; Parsons, HG | 1 |
| Delport, R; Human, JA; Jerling, JJ; Lagendijk, J; Potgieter, HC; Ubbink, JB; Vermaak, WJ; Vorster, HH | 1 |
| de Graaf, J; Stalenhoef, AF; Stuyt, PM | 1 |
| Alidzhanova, KhG; Buriachkovskaia, LI; Chuĭkin, NA; Eliseev, AO; Kukharchuk, VV; Tripol'skaia, LV; Tvorogova, MG | 1 |
| Cohen, JC; Guerra, R; Johnston, JM; Mooser, V; Stafforini, D; Zhao, B | 1 |
| Ceska, R; Petrásek, J; Sobra, J; Spácil, J | 1 |
| Ames, S; Arensman, F; Brewster, TG; Davidson, M; DuJovne, C; Gormley, GJ; Graham, K; Hopkins, P; Illingworth, DR; Isaacsohn, JL; Jacobsen, CA; Jacobson, MS; Knopp, RH; Kwiterovich, PO; Laskarzewski, PM; Liacouras, CA; Siimes, MA; Stein, EA; Williams, CL | 1 |
| Firth, JC; Hall, JM; Jacobs, P; Marais, AD; Wood, L | 1 |
| Carla, H; Jouanel, P; Malpuech, G; Meyer, M; Palcoux, JB; Tridon, A; Vanlieferinghen, P | 1 |
| Kirchgässler, KU; Schiffner-Rohe, J; Stahlheber, U | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Pino, E; Prat, H; Román, O | 1 |
| Mabuchi, H | 1 |
| Chehne, F; Lupattelli, G; Sinzinger, H | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Crawford, LM | 1 |
| Stein, EA | 1 |
| Bengel, F; Jaeger, BR; Schwaiger, M; Seidel, D; Tsobanelis, T | 1 |
| Bruce, R; Crook, D; Mulcahy, D; Patterson, D; Worthington, M; Wynn, V | 1 |
| Breier, C; Eber, B; Gaul, G; Klein, W; Schmidt, P; Schumacher, M; Silberbauer, K; Stühlinger, W | 1 |
| Idzior-Waluś, B | 3 |
| Ebeling, T; Happonen, P; Miettinen, TA; Pyörälä, K; Turtola, H; Uusitupa, MI; Voutilainen, E | 1 |
| Bruce, R; Crook, D; Sidhu, M | 1 |
| Illingworth, DR; Mahley, RW; Vakar, F; Weisgraber, KH | 1 |
| Illingworth, DR; O'Malley, JP | 2 |
| Berg, K; Foss, OP; Hjermann, I; Leren, P; Leren, TP | 1 |
| Lund, H; Norseth, J; Ose, L; Stugaard, M; Wiig, I | 1 |
| Bacon, S; Illingworth, DR; Pappu, AS; Sexton, GJ | 1 |
| Kerr-Muir, M; Lewis, B; Quiney, J; Slavin, B; Watts, GF | 1 |
| Ball, MJ; Lewis-Barned, NJ | 1 |
| McCoy, E; Yokoyama, S | 1 |
| Haug, E; Lund, H; Norseth, J; Ose, L; Purvis, K; Rui, H; Tollefsrud, A; Viksmoen, L | 1 |
| Aviram, M; Brook, JG; Cogan, U; Dankner, G; Hochgraf, E | 1 |
| Lee, E; Lepre, F | 1 |
| Kotze, MJ; Kriek, JA; Steyn, K; van Zyl, LJ; Weight, MJ | 1 |
| Ebeling, T; Pyörälä, K; Reijonen, T; Turtola, H; Uusitupa, M; Voutilainen, E | 1 |
| Tikkanen, MJ; Tilly-Kiesi, M | 2 |
| Miettinen, TA; Vanhanen, H | 1 |
| Kukharchuk, V; Martinov, A; Pomerantsev, E; Shabalkin, B; Titov, V; Yurenev, A; Zhukova, I | 1 |
| Kochsiek, K; Kromer, EP; Riegger, AJ; Stürmer, W | 1 |
| Bakker, HD; Bruin, T; Kastelein, JJ; Lansberg, PJ; Schaap, MC | 1 |
| Catapano, AL; Corsini, A; Fumagalli, R; Mazzotti, M; Romano, C; Romano, L | 1 |
| Ebeling, T; Happonen, P; Parviainen, M; Pyörälä, K; Turtola, H; Uusitupa, M; Voutilainen, E | 1 |
| Schneider, T; Ulbig, M | 1 |
| Gevers Leuven, JA; Hollaar, L; Smelt, AH; van 't Hooft, FM; van der Laarse, A; Zhao, SP | 1 |
| Ausina Gómez, A; Dalmau Serra, J; Gilsanz Peral, A; Montero Brens, C | 1 |
| Johansson, J; Mölgaard, J; Olsson, AG | 1 |
| Schlienger, JL | 1 |
| Cigala, O; Della Valle, M; Malarbi, AL; Marasco, A; Pancallo, MT | 1 |
| Illingworth, DR; Pappu, AS; Prihoda, JS; Smith, FE | 1 |
| Alessandri, C; Balsano, F; Barsi, R; Basili, S; Censi, C; Cordova, C; Marotta, P; Paradiso, M; Peverini, F | 1 |
| Brocard, JJ; Keller, U; Oberhänsli, A; Riesen, WF | 1 |
| Bakker, HD; Gorter, JW; Kastelein, JJ; Lansberg, PJ; Schilte, PP | 1 |
| Liu, K | 1 |
| Desager, JP; Harvengt, C; Horsmans, Y | 1 |
| Miettinen, TA | 1 |
| Aalto-Setälä, K; Ehnholm, C; Helve, E; Kontula, KK; Ojala, JP; Tikkanen, MJ | 1 |
| Bednarek, M; Broda, G; Chotkowska, E; Kuzmińska, A; Polakowska, M; Rywik, S | 1 |
| Creutzfeldt, C; Creutzfeldt, W; Fölsch, UR; Kirchhoff, S; Nitsche, R; Ramin, V; Schlage, J | 1 |
| Balestrieri, G; Candrina, R; Di Stefano, O; Giustina, G; Salvi, A; Spandrio, S | 1 |
| Mol, MJ; Stalenhoef, AF | 1 |
| Kruse, W; Schlierf, G; Weber, E | 1 |
| Haacke, H; Kirchhoff, R; Spreckelsen, U | 1 |
| MacDonald, JL; Mauro, VF | 1 |
| Helve, E; Ojala, JP; Tikkanen, MJ | 1 |
| Beigel, Y; Djaldetti, M; Fuchs, J; Green, P; Lurie, Y; Snir, M | 1 |
| Erkelens, DW | 1 |
| Hagemenas, FC; Illingworth, DR; Pappu, AS | 1 |
| Aubert, I; Bauduceau, B; Chanu, B; Dachet, C; Emmerich, J; Erlich, D; Gautier, D; Jacotot, B; Rouffy, J | 1 |
| Janning, G; Seidel, D; Thiery, J; Walli, AK | 1 |
| Creutzfeldt, C; Creutzfeldt, W; Seidel, D; Thiery, J; Walli, AK | 1 |
| Dollerup, J; Leth, A; Munch, M; Nielsen, B | 1 |
| Diehl, JC; Havel, RJ; Kane, JP; Malloy, MJ; Phillips, NR; Ports, TA | 1 |
| Escobar Gallego, A; Fernández Gómez, E; García Alegría, JJ; Gascón Luna, F; Masana Marín, L; Mongil Ruiz, I; Obando Santaella, I | 1 |
| Dolan, ET; Grundy, SM; Haddox, RJ; Nozaki, S; Vega, GL | 1 |
| Kohn, IJ; Ribeiro, L | 1 |
| French, J; White, H | 1 |
| Bercher, L; Bovet, P; Brunner, HR; Darioli, R | 1 |
| Burrichter, H; Geisel, J; Oette, K | 1 |
| Carlson, LA | 1 |
| Demacker, PN; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Arnon, R; Eisenberg, S; Israeli, A; Raveh, D | 1 |
| Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ | 1 |
| Ehringer, H; Koppensteiner, R; Minar, E | 1 |
| De Knijff, P; Erkelens, DW; Frants, RR; Gevers Leuven, JA; Havekes, LM; Mol, MJ; Schouten, J; Smit, J; Stalenhoef, AF | 1 |
| Bates, MC; Chillag, S; Grubb, S; Warren, SG | 1 |
| Bacon, SP; Cope, R; Illingworth, DR | 1 |
| Kreisberg, R; Mantell, G; Miller, V; Shapiro, DR; Stein, E; Washington, L | 1 |
| Descoeudres, C; Girod, MA; Mordasini, R; Riesen, WF | 1 |
| Löbel, P; Schrör, K; Steinhagen-Thiessen, E | 1 |
| Jones, PH | 1 |
| Behrens-Baumann, W; Creutzfeldt, C; Morawietz, A; Seidel, D; Thiery, J | 1 |
| Cuthbert, JA; East, CA; Lipsky, PE | 1 |
| Berg, K; Leren, TP | 1 |
| Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Pacovský, V; Procházková, R; Sobra, J; Wilczek, H | 1 |
| Beltz, WF; Juliano, J; Kelly, N; Lester, P; Simmons, D; Steinberg, D; Weinreb, R; Witztum, JL; Young, SG | 1 |
| Bacon, S; Illingworth, DR | 2 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Prager, R | 1 |
| Kuwano, M; Ono, M | 1 |
| Edelman, S; Witztum, JL | 1 |
| Bacon, S; Illingworth, DR; Pappu, AS | 1 |
| Keane, PF; Ohri, SK; Sackier, JM; Swift, I; Thompson, GR; Williamson, RC; Wood, CB | 1 |
| Pluhar, W | 1 |
| Walker, JF | 1 |
| Averna, M; Barbagallo, CM; Davì, G; Mogavero, A; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Anchors, JM; Bailey, KR; Brewer, HB; Fojo, SS; Hoegg, JM; Lackner, KJ | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM; van 't Laar, A | 1 |
| Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P | 1 |
| Harvengt, C; Leclercq, V | 1 |
| Aubert, I; Besseau, M; Chanu, B; Charpak, Y; Dachet, C; Emmerich, J; Herlich, D; Jacotot, B; Rouffy, J | 1 |
| Armstrong, VW; Creutzfeldt, C; Creutzfeldt, W; Schleef, J; Seidel, D; Thiery, J | 1 |
| Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V | 1 |
| Corbin, D; Illingworth, DR | 1 |
| Barnes, K; Chrousos, GP; Hoeg, JM; Laue, L; Loriaux, DL | 1 |
| Berg, K; Foss, OP; Hjermann, I; Leren, P; Leren, TP; Viksmoen, L | 1 |
| Helve, E; Tikkanen, MJ | 1 |
| Brewer, HB; Brittain, EH; Farnsworth, WH; Hoeg, JM; Maher, M; Sherins, RJ | 1 |
| Gevers Leuven, JA; Glatz, JF; Katan, MB; Kempen, HJ; van der Voort, HA | 1 |
| Weisweiler, P | 1 |
| Costa, C; Guarini, G; Vitaliano, E | 1 |
| Baggen, MG; Erkelens, DW; Kettner, M; Koningsberger, JC; Mol, MJ; Van Doormaal, JJ | 1 |
| Erkelens, DW; Gevers Leuven, JA; Mol, MJ; Schouten, JA; Stalenhoef, AF | 1 |
| Berg, K; Foss, OP; Hjermann, I; Leren, P; Leren, T | 1 |
| Bilheimer, DW; East, C; Grundy, SM | 2 |
| Bewley, DZ; Lamkin, GE; Stein, EA | 1 |
| Bilheimer, DM; Grundy, SM; Uauy, R; Vega, GL | 1 |
| Reaven, P; Witztum, JL | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Anchors, MA; Bailey, KR; Bojanovski, M; Fojo, SS; Gregg, RE; Hoeg, JM; Lackner, KJ; Maher, MB; Sprecher, DL; Zech, LA | 1 |
| Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB | 2 |
| Brewer, HB; Hoeg, JM; Starzl, TE | 1 |
| Bilheimer, DW; Cuthbert, JA; East, CA; Lipsky, PE | 1 |
| Ford, J; Jenkinson, M; Thompson, GR; Trayner, I | 1 |
| Escobar, A; Joven, J; Masana, L; Rubiés-Prat, J | 1 |
| Bacon, SR; Bolognese, JA; Frost, PH; Havel, RJ; Hunninghake, DB; Illingworth, DR; Lamkin, GE; Lees, RS; Stein, EA; Tobert, JA | 1 |
| Kane, JP; Kunitake, ST; Malloy, MJ; Tun, P | 1 |
| Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Knight, BL; Patel, DD; Soutar, AK | 1 |
| Endo, A | 2 |
| Bilheimer, DW; Grundy, SM; Vega, GL | 1 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
15 review(s) available for lovastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
The treatment of familial hypercholesterolaemia by partial ileal bypass surgery. A review of the literature.
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Diarrhea; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Methods; Naphthalenes; Niacin; Postoperative Complications | 1984 |
Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Dogs; Drug Therapy, Combination; Heterozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lipoproteins, LDL; Liver; Lovastatin; Naphthalenes; Receptors, LDL | 1983 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
[Clinical studies on hyperlipidemia].
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Blood Component Removal; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin | 1999 |
Statins in children. Why and when.
Topics: Age Factors; Aging; Anticholesteremic Agents; Arteriosclerosis; Child; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Safety; Sex Factors; Treatment Outcome | 2001 |
[Study of LDL receptors and response to lovastatin therapy in familial homozygotic hypercholesterolemia].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL | 1991 |
[Advance in drug treatment of primary and familial hypercholesterolemia].
Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Panax; Plants, Medicinal; Probucol | 1991 |
Simvastatin: a review of its pharmacology and clinical use.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Simvastatin | 1991 |
Efficacy and tolerability of simvastatin (MK-733).
Topics: Adrenal Cortex; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
[Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
Topics: Adult; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin | 1989 |
Somatic cell mutants of low density lipoprotein receptor.
Topics: Animals; Carbohydrate Sequence; Cell Line; Hyperlipoproteinemia Type II; Lovastatin; Molecular Sequence Data; Monensin; Mutation; Receptors, LDL | 1989 |
Drug therapy of hypercholesterolemia.
Topics: Bile Acids and Salts; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Niacin | 1988 |
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1987 |
[Pharmacologic therapy of arteriosclerosis. II. New directions].
Topics: Animals; Anticholesteremic Agents; Arachidonate Lipoxygenases; Arteriosclerosis; Blood Platelets; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Enzyme Induction; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoxygenase Inhibitors; Lovastatin; Male; Models, Biological; Muscle, Smooth, Vascular; Naphthalenes; Phosphatidylcholine-Sterol O-Acyltransferase; Platelet Aggregation; Rats; Receptors, LDL | 1985 |
71 trial(s) available for lovastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Apolipoproteins; Child; Cholesterol, LDL; Female; Growth; Heterozygote; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin | 2005 |
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Topics: Cholesterol; Cholesterol, Dietary; Clinical Trials as Topic; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Naphthalenes; Time Factors; Triglycerides | 1984 |
Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS).
Topics: Aged; Anticholesteremic Agents; Calcium; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Tomography, X-Ray Computed | 1995 |
Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia.
Topics: Adult; Aged; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Prospective Studies; Treatment Outcome | 1995 |
Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy.
Topics: Adult; Creatine Kinase; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Myoglobin; Physical Exertion; Simvastatin | 1995 |
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Topics: Apolipoproteins B; Apoproteins; Blood Platelets; Cholesterol; Coenzymes; Cross-Over Studies; Electrocardiography; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Myoglobin; Oxidation-Reduction; Simvastatin; Treatment Outcome; Triglycerides; Ubiquinone | 1994 |
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1995 |
[Simvastatin in the treatment of familial hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Topics: Adult; Blood Component Removal; Cholestyramine Resin; Colestipol; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Middle Aged; Odds Ratio; Simvastatin | 1995 |
The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study.
Topics: Adolescent; Adult; Aged; Blood Platelets; Cyclic AMP; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Eicosanoid; Second Messenger Systems; Thromboxanes | 1993 |
The effect of dietary fat content on plasma noncholesterol sterol concentrations in patients with familial hypercholesterolemia treated with simvastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Sterols | 1994 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Electronics; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Patient Compliance; Single-Blind Method; Time Factors | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Topics: Adolescent; Alanine Transaminase; Anticholesteremic Agents; Apolipoproteins A; Aspartate Aminotransferases; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Patient Compliance; Placebos; Safety | 1996 |
Fish oil supplementation in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Olive Oil; Plant Oils; Simvastatin; Time Factors | 1996 |
Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Mutation; Norway; Receptors, LDL; Triglycerides | 1995 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Blood Viscosity; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Combined Modality Therapy; Enzyme Inhibitors; Erythrocyte Aggregation; Erythrocyte Deformability; Erythrocyte Membrane; Female; Fibrinogen; Hemorheology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Membrane Lipids; Middle Aged; Phospholipids | 1996 |
[A trial of long-term lovastatin treatment in patients with a heterozygous form of hereditary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Combined Modality Therapy; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Plasmapheresis; Retrospective Studies; Time Factors | 1997 |
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
Topics: Adolescent; Anticholesteremic Agents; Apolipoproteins; Blood Chemical Analysis; Child; Creatine Kinase; Double-Blind Method; Growth; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Nutritional Status; Sexual Maturation; Transaminases | 1999 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1997 |
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1999 |
Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Combined Modality Therapy; Delayed-Action Preparations; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides | 1992 |
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
Topics: Adult; Cholesterol; Cholestyramine Resin; Dietary Fiber; Female; Galactans; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Mannans; Middle Aged; Plant Gums; Sterols | 1992 |
Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Family; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged | 1992 |
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy].
Topics: Adolescent; Adult; Aged; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Middle Aged | 1992 |
Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Drug Administration Schedule; Drug Resistance; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Triglycerides | 1992 |
The cost of simvastatin therapy in treatment of hypercholesterolaemia in a hospital lipid clinic.
Topics: Anticholesteremic Agents; Drug Costs; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin | 1992 |
Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides | 1992 |
Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II.
Topics: Adult; Aged; Angina Pectoris; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Exercise Test; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged | 1992 |
Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Pressure; Body Weight; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Galactans; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Mannans; Middle Aged; Plant Gums | 1991 |
[Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Topics: Anticholesteremic Agents; Cholesterol; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Simvastatin; Single-Blind Method; Transaminases; Triglycerides | 1991 |
Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins B; Apolipoproteins E; Deoxyribonucleases, Type II Site-Specific; Female; Genotype; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic | 1991 |
Influence of the HMG-CoA-reductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile.
Topics: Adult; Aged; Bile; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Prospective Studies; Time Factors | 1991 |
Cortisol secretion in patients on simvastatin.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Adrenocortical function in patients on simvastatin.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Anticholesteremic Agents; Clinical Trials as Topic; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1990 |
Monitoring compliance in clinical trials.
Topics: Anticholesteremic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Hyperlipoproteinemia Type II; Lovastatin; Microcomputers; Patient Compliance; Simvastatin | 1990 |
Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels.
Topics: Blood Viscosity; Dose-Response Relationship, Drug; Drug Evaluation; Erythrocyte Deformability; Female; Fibrinogen; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Platelet Count | 1991 |
The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Heterozygote; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Receptors, LDL; Simvastatin | 1990 |
Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia.
Topics: Child, Preschool; Cholesterol, LDL; Combined Modality Therapy; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Plasmapheresis; Xanthomatosis | 1990 |
[Treatment of severe primary hypercholesterolemia with lovastatin (Mevacor). A new therapeutic principle].
Topics: Adult; Aged; Denmark; Drug Evaluation; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged | 1990 |
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Radiographic Image Interpretation, Computer-Assisted; Triglycerides | 1990 |
Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged | 1990 |
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Cataract; Cholesterol; Cholestyramine Resin; Creatine Kinase; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1990 |
Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
Topics: Cholesterol; Clinical Trials as Topic; Colestipol; Drug Interactions; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Phenols; Polyamines; Probucol; Prospective Studies; Triglycerides; Xanthomatosis | 1989 |
Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gemfibrozil; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides | 1989 |
Adrenocortical function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin).
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Heterozygote; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Lovastatin | 1987 |
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1989 |
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1988 |
Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged | 1988 |
Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
Topics: Apolipoproteins; Clinical Trials as Topic; Genetic Carrier Screening; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipase; Lipoprotein Lipase; Lipoproteins; Lovastatin; Phenols; Probucol; Random Allocation | 1988 |
Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.
Topics: Adult; Cholesterol; Cholesterol, HDL; Follicle Stimulating Hormone; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Luteinizing Hormone; Male; Middle Aged; Naphthalenes; Neomycin; Pituitary Function Tests; Prolactin; Testis | 1987 |
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Sterol O-Acyltransferase | 1988 |
Clinical experience with simvastatin compared with cholestyramine.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1988 |
[At last, an effective treatment of familial hypercholesterolemia?].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged | 1988 |
Combination drug therapy for familial combined hyperlipidemia.
Topics: Adult; Cholelithiasis; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pentanoic Acids; Polyamines; Random Allocation; Ultrasonography; Valerates | 1988 |
Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Naphthalenes; Placebos; Random Allocation; Triglycerides | 1986 |
The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin | 1986 |
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.
Topics: Adult; Alanine Transaminase; Apolipoproteins B; Cataract; Cholesterol; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Random Allocation | 1987 |
157 other study(ies) available for lovastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
Topics: Adult; Aged; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Diet, Fat-Restricted; Dietary Supplements; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Monascus; Mutation; Phenotype; Time Factors; Treatment Outcome; Young Adult | 2017 |
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cells, Cultured; Fibroblasts; Flow Cytometry; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases | 2014 |
The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Mevalonic Acid; Middle Aged; Periodicity; Probability; Prospective Studies; Sampling Studies; Simvastatin; Urinalysis | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Mevalonic Acid; Middle Aged; Simvastatin | 2003 |
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Topics: Anticholesteremic Agents; Coenzymes; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Ubiquinone | 2004 |
Lowering plasma cholesterol by raising ldl receptors. 1981.
Topics: Animals; Anticholesteremic Agents; Cholesterol; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL | 2004 |
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
Topics: Colestipol; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin | 2004 |
Modulation of human lymphocyte responses by low density lipoproteins (LDL): enhancement but not immunosuppression is mediated by LDL receptors.
Topics: Child; DNA Replication; Female; Humans; Hyperlipoproteinemia Type II; Immunosuppression Therapy; Lipoproteins, LDL; Lovastatin; Lymphocyte Activation; Lymphocytes; Mevalonic Acid; Naphthalenes; Phytohemagglutinins; Receptors, Cell Surface; Receptors, LDL | 1984 |
Lowering plasma cholesterol by raising LDL receptors.
Topics: Animals; Cholesterol; Dogs; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Middle Aged; Naphthalenes; Receptors, Cell Surface; Receptors, LDL | 1981 |
Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Naphthalenes | 1984 |
Hypercholesterolemia persisting after distal ileal bypass: response to mevinolin.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Ileum; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Middle Aged; Naphthalenes | 1984 |
Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Polyamines | 1984 |
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Naphthalenes; Triglycerides | 1984 |
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
Topics: Anticholesteremic Agents; Colestipol; Genetic Carrier Screening; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipoproteins, LDL; Lovastatin; Naphthalenes; Polyamines | 1983 |
Regulation of LDL receptors in vivo.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cricetinae; Feedback; Guinea Pigs; Heterozygote; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipoproteins, LDL; Liver; Lovastatin; Macaca mulatta; Naphthalenes; Rabbits; Rats; Receptors, LDL | 1984 |
Effects of probucol on homozygous cases of familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Energy Intake; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasma Exchange; Probucol; Skin Diseases; Tendons; Triglycerides; Xanthomatosis | 1983 |
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phospholipids; Triglycerides | 1983 |
Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols | 1981 |
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Naphthalenes; Triglycerides; Ubiquinone | 1981 |
Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.
Topics: Adult; Blood Coagulation; Body Mass Index; Cholesterol; Cholesterol, LDL; Chromatography, Gel; Endothelium, Vascular; Female; Heparin; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Triglycerides | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Continued benefit of lovastatin in the treatment of hypercholesterolemia in 36 patients.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Treatment Failure; Treatment Outcome | 1995 |
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Topics: Age Factors; Animals; Aorta; Aorta, Thoracic; Arteriosclerosis; Carbachol; Cholesterol; Endothelium, Vascular; Heterozygote; Homozygote; Hyperlipoproteinemia Type II; Lovastatin; Phenylephrine; Rabbits; Simvastatin; Vasoconstriction; Vasodilation | 1995 |
Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.
Topics: Adult; Arginine; Blood Pressure; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Infusions, Intravenous; Lovastatin; Male; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Serotonin; Simvastatin; Vasodilation | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
Topics: Adult; Apolipoproteins B; Eating; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides; Vitamin A; Wolman Disease | 1994 |
In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
Topics: Female; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Pravastatin; Receptors, LDL | 1994 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Polymerase Chain Reaction; Simvastatin | 1995 |
Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
Topics: Alleles; Analysis of Variance; Blotting, Southern; Deoxyribonucleases, Type II Site-Specific; DNA; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Receptors, LDL; Treatment Outcome | 1995 |
[Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia].
Topics: Adult; Calcitriol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Vitamin D | 1994 |
[Biochemical and functional study of the liver during treatment of familial hyperlipoproteinemia with Mevacor (lovastatin) and Vasosan S (cholestyramine)].
Topics: Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Middle Aged | 1994 |
A small step for gene therapy.
Topics: Adenosine Deaminase; Adult; Advisory Committees; beta-Thalassemia; Cells, Cultured; Child; Child, Preschool; Combined Modality Therapy; Ethics Committees, Research; Federal Government; Female; Genetic Diseases, Inborn; Genetic Research; Genetic Therapy; Globins; Government Regulation; Health Policy; Humans; Hyperlipoproteinemia Type II; Liver; Lovastatin; Lymphocytes; Middle Aged; Receptors, LDL; Recombinant Proteins; Severe Combined Immunodeficiency | 1994 |
Heroic gene surgery.
Topics: Adult; Animals; Biopsy; Cells, Cultured; Combined Modality Therapy; Contraindications; Ethics, Medical; Female; Genetic Diseases, Inborn; Genetic Therapy; Hepatectomy; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Liver; Lovastatin; Rabbits; Receptors, LDL; Recombinant Proteins; Risk Assessment | 1994 |
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia.
Topics: Adult; Biopsy; Cells, Cultured; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Gene Expression Regulation; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Humans; Hyperlipoproteinemia Type II; In Situ Hybridization, Fluorescence; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Receptors, LDL; Recombinant Proteins; Safety; Up-Regulation | 1994 |
[The thrombocyte function of subjects with atherogenic hyperlipidemias during lovastatin treatment].
Topics: Adenosine Diphosphate; Arteriosclerosis; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Time Factors | 1993 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
Lovastatin enhances hepatic uptake of low density lipoprotein in humans.
Topics: Adult; Apolipoproteins B; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Iodine Radioisotopes; Lipoproteins, LDL; Liver; Lovastatin; Lung; Male; Middle Aged; Myocardium; Technetium | 1993 |
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Pedigree; Polymorphism, Genetic; Probucol; Receptors, LDL; Simvastatin | 1993 |
The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells.
Topics: Anticholesteremic Agents; Cholesterol; Dietary Fats; Gold Colloid; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins, LDL; Lovastatin; Receptors, LDL; Simvastatin | 1993 |
The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
Topics: Adult; Apolipoproteins E; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Receptors, LDL; Retrospective Studies | 1993 |
Time response of cholesterol synthesis inhibition by compactin-related compounds. In vitro quantitation of the "escape phenomenon".
Topics: Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Lovastatin; Naphthalenes; Skin; Tumor Cells, Cultured | 1993 |
Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Mutation; Receptors, LDL; Simvastatin; South Africa | 1993 |
Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.
Topics: Base Sequence; Blotting, Southern; Child; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dietary Fats; Drug Therapy, Combination; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Molecular Sequence Data; Mutation; Pedigree; Receptors, LDL; Simvastatin | 1995 |
Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Topics: Anticholesteremic Agents; Canada; Cells, Cultured; Enzyme Induction; Enzyme Inhibitors; Ethnicity; Female; Fibroblasts; France; Gene Expression Regulation; Haploidy; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Prevalence; Receptors, LDL; RNA, Messenger; Sequence Deletion; Transcription, Genetic; Treatment Failure | 1996 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Binding, Competitive; Cells, Cultured; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Receptors, LDL; Simvastatin; Triglycerides | 1996 |
Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, Dietary; Combined Modality Therapy; Diet, Fat-Restricted; Erythrocyte Deformability; Erythrocyte Membrane; Female; Fibrinogen; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Membrane Lipids; Middle Aged; Phospholipids | 1996 |
Results of intensive long-term treatment of familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atrial Natriuretic Factor; Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Probucol; Quality of Life; Treatment Outcome | 1996 |
[The characteristics of the hypolipidemic effect of Mevacor with its permanent multiyear use].
Topics: Adult; Aged; Child; Diseases in Twins; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Time Factors | 1996 |
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
Topics: Animals; Apolipoprotein B-100; Apolipoproteins A; Apolipoproteins B; Cats; Child, Preschool; Cholesterol, LDL; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Immunoblotting; Lovastatin; Male; Middle Aged; Pedigree; Phenotype; Receptors, LDL; Simvastatin; Treatment Outcome | 1997 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of the patient with primary familial heterozygous hypercholesterolemia.
Topics: Aged; Colestipol; Coronary Disease; Diet, Fat-Restricted; Drug Therapy, Combination; Exercise; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Weight Loss | 1995 |
Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; B-Lymphocytes; Cell Culture Techniques; Cell Division; Cell Membrane; Cell Transformation, Viral; Child; DNA; Female; Fibroblasts; Herpesvirus 4, Human; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Receptors, LDL | 1997 |
The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lovastatin; Male; Middle Aged; Simvastatin; Ubiquinone; Vitamin E | 1997 |
Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Antifungal Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Ketoconazole; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Treatment Outcome | 1997 |
Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Age Factors; Cholesterol, LDL; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypobetalipoproteinemias; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Pedigree; Phospholipases A; Regression Analysis; Sex Factors | 1997 |
[Favorable effect of treatment with statins on the intima of the common carotid artery in patients with familial hyperlipoproteinemia].
Topics: Anticholesteremic Agents; Carotid Artery, Common; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin; Tunica Intima; Ultrasonography | 1997 |
Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience.
Topics: Adolescent; Adult; Child; Cholesterol; Combined Modality Therapy; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Plasma Exchange; Receptors, LDL; Treatment Outcome | 1993 |
Treatment of homozygous familial hypercholesterolemia by plasma exchange and LDL-apheresis.
Topics: Adolescent; Blood Volume; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Plasma Exchange; Plasmapheresis | 1993 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation?
Topics: Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Pain; Pain Measurement; Treatment Outcome; Vitamin A | 2000 |
Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy.
Topics: Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Peroxides; Lovastatin; Male; Middle Aged; Muscular Diseases; Pain | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
From the Food and Drug Administration.
Topics: Adolescent; Antibodies, Monoclonal; Anticholesteremic Agents; Antineoplastic Agents; Humans; Hyperlipoproteinemia Type II; Indium Radioisotopes; Lovastatin; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; United States; United States Food and Drug Administration; Yttrium Radioisotopes | 2002 |
Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Blood Component Removal; Chemical Precipitation; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Extracorporeal Circulation; Female; Fibrinolytic Agents; Heparin; Humans; Hyperlipoproteinemia Type II; Lovastatin; Treatment Outcome | 2002 |
Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
[Examination of cortisol and insulin levels in serum of patients with primary hyperlipoproteinemia and phenotype IIa and IIb during lovastatin treatment].
Topics: Adult; Aged; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Insulin; Lovastatin; Male; Middle Aged | 1992 |
[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb].
Topics: Antithrombin III; Factor VII; Humans; Hyperlipoproteinemia Type II; Lovastatin; Phenotype; Plasminogen | 1992 |
[Influence of lovastatin on serum lipids in patients with primary hyperlipidemia and phenotype IIa and IIB. II. Changes of lipid composition of plasma lipoprotein fractions after lovastatin administration].
Topics: Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Phenotype | 1992 |
Simvastatin and lipoprotein(a)
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Apolipoprotein epsilon 4 and coronary artery disease.
Topics: Apolipoproteins E; Child; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Phenotype; Sex Factors | 1992 |
Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Cholestyramine Resin; Drug Therapy, Combination; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Time Factors | 1992 |
One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin.
Topics: Child, Preschool; Cholesterol Esters; Cholestyramine Resin; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism, Inborn Errors; Lovastatin; Male | 1992 |
Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Heterozygote; Hormones; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Single-Blind Method; Spermatozoa; Testis | 1992 |
Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies.
Topics: Animals; Biological Transport; Cells, Cultured; Cholesterol Esters; Diphenylhexatriene; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Macrophages; Mice; Oxidation-Reduction | 1992 |
Response to treatment with simvastatin in a compound FH heterozygote.
Topics: Adult; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1992 |
Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Centrifugation, Density Gradient; Chemical Fractionation; Cholesterol Esters; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Triglycerides | 1992 |
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Middle Aged; Phytosterols; Pravastatin; Sitosterols; Triglycerides | 1992 |
[Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Triglycerides | 1991 |
The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Child; Cholesterol; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Lymphocytes; Male; Predictive Value of Tests; Receptors, Cell Surface; Receptors, Lipoprotein; Simvastatin; Triglycerides | 1991 |
Poor response to simvastatin in familial defective apo-B-100.
Topics: Anticholesteremic Agents; Apolipoproteins B; Humans; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL; Simvastatin | 1991 |
[Absence of cataractogenic effect of lovastatin (Mevinacor) so far].
Topics: Adult; Aged; Cataract; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Lens, Crystalline; Lovastatin; Male; Middle Aged; Prospective Studies | 1991 |
Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Particle Size; Regression Analysis; Simvastatin; Triglycerides | 1991 |
Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholesterol, VLDL; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Particle Size; Simvastatin; Triglycerides | 1991 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
[Simvastatin in the treatment of hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cholesterol; Drug Evaluation; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Mevalonic Acid; Middle Aged; Simvastatin | 1991 |
[Effects of simvastatin on atherogenic blood lipid pattern].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1991 |
[A patient with the homozygote form of familial hypercholesterolemia].
Topics: Anticholesteremic Agents; Child; Exercise Test; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides | 1991 |
Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.
Topics: Adolescent; Adult; Anticholesteremic Agents; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Simvastatin | 1991 |
Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
Topics: Cholesterol, Dietary; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Lovastatin; Naphthalenes; Pravastatin | 1991 |
[Lovastatin in the treatment of primary hypercholesterolemia].
Topics: Adult; Aged; Apolipoproteins B; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Triglycerides | 1991 |
[Cholestatic jaundice during lovastatin medication].
Topics: Cholestasis; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Time Factors | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia.
Topics: Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin | 1991 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
[Homozygous familial hypercholesterolemia. Response to combined cholestyramine and lovastatin therapy].
Topics: Child, Preschool; Cholestyramine Resin; Drug Therapy, Combination; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male | 1990 |
[New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
Topics: Cholesterol; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin | 1990 |
The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins E; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Phenotype | 1990 |
Misconceptions about cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Attitude; Cholesterol; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; New Zealand; Simvastatin | 1990 |
[Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Apoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins.
Topics: Apolipoproteins; Centrifugation, Zonal; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Monocytes; Receptors, LDL | 1990 |
Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
Topics: Adult; Aged; Cholesterol, LDL; Colestipol; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Polyamines; Probucol; Triglycerides | 1990 |
Effect of lovastatin on hemorheology in type II hyperlipoproteinemia.
Topics: Aged; Arteriosclerosis; Blood Viscosity; Cholesterol; Erythrocyte Aggregation; Female; Fibrinogen; Hematocrit; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Platelet Aggregation; Rheology; Triglycerides | 1990 |
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sex Factors; Simvastatin | 1990 |
Effectiveness of low-dose lovastatin in lowering serum cholesterol. Experience with 56 patients.
Topics: Cholesterol; Drug Administration Schedule; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Prospective Studies; Time Factors | 1990 |
Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin.
Topics: Achilles Tendon; Adult; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Radiography; Remission Induction; Tendons; Wolman Disease | 1990 |
[Selective elimination of atherogenic lipoproteins using dextran-sulfate cellulose. Experiences in 2 patients with heterozygote familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Cellulose; Combined Modality Therapy; Dextran Sulfate; Dextrans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Plasmapheresis; Simvastatin | 1989 |
Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Topics: Adenosine Triphosphate; Adult; Aged; Anticholesteremic Agents; Blood Platelets; Cyclic AMP; Epoprostenol; Humans; Hyperlipoproteinemia Type II; Iloprost; Lipids; Lovastatin; Middle Aged; Platelet Aggregation; Receptors, Epoprostenol; Receptors, Prostaglandin; Simvastatin; Thromboxane B2 | 1989 |
The use of combined LDL affinity apheresis utilizing dextran sulfate cellulose columns and hypolipidemic medications in patients with severe hypercholesterolemia to assess regression of atherosclerosis.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Blood Component Removal; Cellulose; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Dextran Sulfate; Dextrans; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Plasmapheresis; Remission Induction | 1988 |
Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
Topics: Cataract; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Normalization of LDL receptor function by lymphocytes of patients with heterozygous familial hypercholesterolemia after treatment with plasma cholesterol lowering agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Drug Combinations; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, LDL; Lovastatin; Lymphocytes; Receptors, Cell Surface; Receptors, Lipoprotein; Reference Values | 1989 |
Unchanged serum lipoprotein (a) concentrations with lovastatin.
Topics: Drug Administration Schedule; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Time Factors | 1989 |
[Iatropathogenic effect of Mevacor on vitamin D metabolism].
Topics: Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Vitamin D | 1989 |
Hyperkalemia during treatment with HMG-CoA reductase inhibitor.
Topics: Adult; Diabetes Mellitus, Type 1; Humans; Hyperkalemia; Hyperlipoproteinemia Type II; Hypertension; Kidney Diseases; Lovastatin; Male | 1989 |
Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Kinetics; Lovastatin; Male; Mevalonic Acid; Middle Aged | 1989 |
Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Jejunoileal Bypass; Lovastatin; Male; Middle Aged; Recurrence; Reoperation | 1989 |
[Treatment of familial hypercholesterolemia using Mevacor. Initial experience].
Topics: Adolescent; Adult; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged | 1989 |
[A case of possible lovastatin-induced pancreatitis in concomitant Gilbert syndrome].
Topics: Acute Disease; alpha-Amylases; Bilirubin; Gilbert Disease; Humans; Hyperbilirubinemia, Hereditary; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Pancreatitis; Risk Factors | 1989 |
Simvastatin: the clinical profile.
Topics: Aged; Creatine Kinase; Drug Therapy, Combination; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Middle Aged; Simvastatin; Transaminases | 1989 |
Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Platelet Aggregation; Simvastatin; Thromboxane B2 | 1989 |
Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Mevalonic Acid | 1989 |
Cholesterol synthesis inhibitors in hyperlipidaemia.
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
Topics: Adult; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles].
Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin | 1988 |
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Female; Heterozygote; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Naphthalenes | 1985 |
The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Child; Cholesterol, LDL; Corticotropin-Releasing Hormone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Metabolism, Inborn Errors; Lovastatin; Male; Naphthalenes; Pituitary-Adrenal System; Receptors, LDL; Steroids | 1987 |
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Simvastatin | 1988 |
[Lovastatin in hyperlipemia of the nephrotic syndrome].
Topics: Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Humans; Hyperlipoproteinemia Type II; Lovastatin | 1988 |
Assessment of functional low-density lipoprotein receptor activity on lymphocytes of normal subjects and patients with familial hypercholesterolemia.
Topics: Cell Division; Cholesterol, LDL; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Lymphocytes; Mevalonic Acid; Receptors, LDL | 1988 |
Lovastatin alone and in combination for treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Anion Exchange Resins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance | 1988 |
Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover.
Topics: Apolipoproteins B; Child; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Receptors, LDL | 1988 |
Lovastatin, nicotinic acid, and rhabdomyolysis.
Topics: Adult; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Niacin; Rhabdomyolysis | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolemia following liver transplantation.
Topics: Anticholesteremic Agents; Child; Combined Modality Therapy; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Liver Transplantation; Lovastatin; Naphthalenes; Receptors, LDL | 1986 |
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.
Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Transplantation; Lovastatin; Male; Naphthalenes; Niacin; Plasma Exchange; Skin Diseases; Xanthomatosis | 1987 |
Detection of familial hypercholesterolemia by assaying functional low-density-lipoprotein receptors on lymphocytes.
Topics: Cells, Cultured; Cholesterol, LDL; Diagnosis, Differential; DNA; Female; Genetic Carrier Screening; Homozygote; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Lymphocyte Activation; Lymphocytes; Male; Methods; Naphthalenes; Receptors, LDL | 1986 |
Lipoprotein fractions and receptors: a role for probucol?
Topics: Anticholesteremic Agents; Biological Transport; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, VLDL; Lovastatin; Naphthalenes; Phenols; Probucol; Receptors, LDL | 1986 |
Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Triglycerides | 1986 |
Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Male; Middle Aged; Naphthalenes | 1986 |
Comparison of six pharmacologic regimens for hypercholesterolemia.
Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Retrospective Studies | 1987 |
[Treatment with mevinolin in a patient with pseudo-homozygous hypercholesterolemia].
Topics: Anticholesteremic Agents; Diagnosis, Differential; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Naphthalenes | 1987 |
Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Polyamines | 1987 |
Long term administration of lovastatin in the treatment of hypercholesterolaemia.
Topics: Adult; Cholesterol; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged | 1987 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasmapheresis; Probucol; Xanthomatosis | 1986 |
Regulation of synthesis and cell content of the low-density-lipoprotein receptor protein in cultured fibroblasts from normal and familial hypercholesterolaemic subjects.
Topics: Acetates; Cell Membrane; Cells, Cultured; Cholesterol; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Immunochemistry; Lipoproteins; Lovastatin; Methionine; Naphthalenes; Radioimmunoassay; Receptors, LDL | 1987 |
Drugs inhibiting HMG-CoA reductase.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols | 1985 |
Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Bile Acids and Salts; Cholesterol; Colestipol; Combined Modality Therapy; Drug Therapy, Combination; Enterohepatic Circulation; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Ileum; Kinetics; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Naphthalenes | 1985 |
HMG-CoA reductase inhibitors.
Topics: Animals; Cell Division; Cells, Cultured; Cholesterol; Drug Resistance; Enzyme Induction; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Naphthalenes; Structure-Activity Relationship | 1985 |